Brief: Regeneron Phase 2 Trial Shows Trevogrumab Prevents Muscle Loss During GLP-1 Weight Loss
01/10/2026 17:19
BRIEF-Regeneron Phase 2 Trial Shows Trevogrumab Prevents Muscle Loss During GLP-1 Weight Loss Oct 1 (Reuters) - Regeneron Pharmaceuticals, Inc. REGN.O:
PHASE 2 COURAGE TRIAL CONFIRMS TREVOGRUMAB PREVENTS LEAN MASS AND MUSCLE LOSS DURING GLP-1 RECEPTOR AGONIST-INDUCED WEIGHT LOSS
REGENERON PHARMACEUTICALS, - TREVOGRUMAB PREVENTS 70% OF MUSCLE LOSS ASSOCIATED WITH SEMAGLUTIDE TREATMENT
REGENERON PHARMACEUTICALS, - PLANS PHASE 2 TRIAL OF TREVOGRUMAB WITH GLP-1 THERAPIES IN OLDER ADULTS
REGENERON PHARMACEUTICALS, - LOWER DOSES OF TREVOGRUMAB WELL TOLERATED WITH 77% EXPERIENCING AT LEAST ONE ADVERSE EVENT
Source text: ID:nGNXbpVm3B
Further company coverage: REGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement